New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
07:19 EDTELN, BIIBBiogen price target raised to $170 from $150 at RBC Capital
After Biogen (BIIB) acquired Elan's (ELN) stake in Tysabri, RBC Capital thinks the deal makes sense from a strategic financial perspective, as it will raise Biogen's margins and lower its tax rate. The firm thinks the company's SG&A as a percentage of revenue will also decline following the deal and it maintains an Outperform rating on the shares.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:48 EDTBIIBBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
08:53 EDTBIIBBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
08:51 EDTBIIBBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
12:22 EDTBIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use